Product Images Fesoterodine Fumarate
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 9 images provide visual information about the product associated with Fesoterodine Fumarate NDC 31722-034 by Camber Pharmaceuticals, Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
camber - camber
camberlogo - camberlogo
fesoterodine-4mg-30s - fesoterodine 4mg 30s
Each extended-release tablet of CAMBE contains 4 mg of fesoterodine fumarate. The usual dosage information can be found in the package insert. The tablets should be stored at 20° to 25°C (68° to 77°F) in a controlled room temperature area and protected from moisture. They should be swallowed whole and not chewed, divided, or crushed. For more details, contact Camber Pharmaceuticals, Inc. at 1-866-495-1995.*
fesoterodine-8mg-30s - fesoterodine 8mg 30s
This text provides information about a medication called CAMBE, which is an extended-release, film-coated tablet containing 8 mg of fesoterodine fumarate. The usual dosage details can be found in the package insert. It is recommended to store the tablets at a temperature range of 20°C to 25°C (68°F to 77°F) and to protect them from moisture. The tablets should be swallowed whole and not chewed, divided, or crushed. The contact number for the U.S. is provided as 1-866-495-1995. The tablets are manufactured by Annora Pharma Pvt. Ltd. in Sangareddy, Telangana, India, and for distribution by Camber Pharmaceuticals, Inc. in Piscataway, NJ, USA.*
figure-1 - figure 1
This is not-available.*
figure-2 - figure 2
This is a figure illustrating the change in urge incontinence episodes per 24 hours in Study 1. The data shows the reduction in episodes of urge incontinence among participants after treatment with Fesoterodine Fumarate extended-release tablets at different doses - 4 mg and 8 mg. The graph displays a decrease in episodes over time for both treatment groups.*
figure-3 - figure 3
figure-4 - figure 4
This text appears to mention a study related to urge incontinence episodes over a 24 hour period. It includes a placebo group, a group using Famtenna for 4 grams, and a group using Festedin. The study seems to be comparing the effectiveness of these treatments in reducing urge incontinence episodes.*
structure - structure
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.